Dr. Landgren on Managing Toxicities of Multiple Myeloma Treatment

C. Ola Landgren, MD, PhD
Published: Monday, Apr 03, 2017



C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses managing toxicities associated with multiple myeloma treatment.

While every drug has its own levels of efficacy and toxicity, Landgren says management of toxicities in multiple myeloma treatment comes down to oral clinical exam, monitoring labs and being aware of the safety profiles of each drug.

Physicians should be informing their patients about side effects throughout treatment, as every case is unique and dosage might need to be altered to suit the individual needs of a given patient.
 
SELECTED
LANGUAGE


C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses managing toxicities associated with multiple myeloma treatment.

While every drug has its own levels of efficacy and toxicity, Landgren says management of toxicities in multiple myeloma treatment comes down to oral clinical exam, monitoring labs and being aware of the safety profiles of each drug.

Physicians should be informing their patients about side effects throughout treatment, as every case is unique and dosage might need to be altered to suit the individual needs of a given patient.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x